News

Genentech and AC Immune partner again
Enlarge image

BusinessSwitzerland

Genentech and AC Immune partner again

19.06.2012 - Six years after their first alliance, Swiss AC Immune SA partners again with US-American Genentech Inc.

Basel/Lausanne – The subject of the new cooperation remained the same: fighting Alzheimer's disease. Therefore the Roche subsidiary has now in-licensed a second generation of AC Immune's antibodies - this time directed to bind the Tau protein. Under the terms of the agreement, AC Immune will receive an undisclosed upfront payment and research, development and commercialisation milestone payments totalling more than CHF400m. Additionally, AC Immune could pocket royalties on net sales resulting from the collaboration – if the product is approved.

Under the multi-year joint research collaboration, AC Immune will work in partnership with Genentech to identify and formulate several pre-clinical candidates. The pharma will have global responsibility for pre-clinical and clinical development, manufacturing and commercialisation of antibodies resulting from the collaboration. Scientifically, both partners are building on the first alliance as the new Tau antibodies are thought to flank Crenezumab, an antibody in phase II resulting from the first cooperation that binds amyloid-beta-plaques (abeta).

By blocking Tau- fibrillation and destroying abeta aggregates, AC Immune attacks the two crucial steps in Alzheimer development. AC Immune has raised CHF64m since its foundation in 2003. Financiers are business angels from Switzerland and prominent biotech supporters like Dietmar Hopp, the founder of the German business software maker SAP. Beside the out- licensed antibody projects, AC immune develops a proprietary small molecule pipeline

http://www.european-biotechnology-news.com/news/news/2012-02/genentech-and-ac-immune-partner-again.html

BusinessGermany

24.08.2014 Germany's Morphosys is licensing a preclinical bi-specific antibody for the treatment of prostate cancer from Emergent Biosolutions. The US developer will rake in up to €138m for the commercialisation rights to the compound.

BusinessUK

20.08.2014 Biopharmaceutical contract manufacturer Fujifilm Diosynth Biotechnologies is expanding its cell culture manufacturing capacity further with a new 2,000l single-use bioreactor at the company’s site in Billingham, UK.

BusinessEUGermanyUK

15.08.2014 Some of Europe’s biggest pharma companies are competing in a bidding war for US biotech Intermune Inc., Bloomberg reports, citing insider reports as the source.

ResearchEUGermanyUK

13.08.2014 The Ebola epidemic is still raging on in West Africa and thus far there is

neither vaccine nor cure for the viral disease. The only flickers of hope:

an experimental antibody serum and an early-stage vaccine.

BusinessFrance

11.08.2014 Will Sanofi succeed where Pfizer failed? The French pharmaceutical company has taken on the commercialisation of Mannkind Corporation’s inhaled insulin product Afrezza.

ResearchSwedenGermany

08.08.2014 Boehringer Ingelheim is walking away from Swedish Orexo's prostaglandin inhibition project OX-MPI. Germany's largest researching pharmaceutical company had been responsible for the project's research and development since 2005.

ResearchSwitzerlandDenmark

06.08.2014 Roche is re-expanding its involvement in RNAi technologies. The Swiss pharmaceutical company will pay up to €335m for the acquisition of the Danish company Santaris Pharma A/S.

ResearchUKSwitzerland

03.08.2014 In its efforts to become the leading country in genetic research, the UK has attracted investments worth more than £300m (€376m) to map 100,000 human genomes by 2017.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • EVOTEC3.94 EUR8.54%
  • VITA 343.90 EUR4.00%
  • SANTHERA86.50 CHF3.59%

FLOP

  • WILEX2.30 EUR-2.54%
  • 4SC1.22 EUR-2.40%
  • ADDEX3.99 CHF-1.97%

TOP

  • SANTHERA86.50 CHF32.1%
  • BB BIOTECH144.50 EUR9.3%
  • BASILEA103.90 CHF4.4%

FLOP

  • WILEX2.30 EUR-17.9%
  • MOLOGEN7.84 EUR-17.5%
  • 4SC1.22 EUR-14.1%

TOP

  • SANTHERA86.50 CHF3831.8%
  • CO.DON2.57 EUR221.2%
  • PAION2.46 EUR182.8%

FLOP

  • CYTOS0.26 CHF-93.5%
  • MEDIGENE4.55 EUR-66.9%
  • THERAMETRICS0.08 CHF-42.9%

No liability assumed, Date: 27.08.2014